MARKET

EIGRQ

EIGRQ

Eiger Biopharma
OTCPK
2.260
-0.490
-17.82%
Closed 10:37 05/17 EDT
OPEN
2.260
PREV CLOSE
2.750
HIGH
2.260
LOW
2.260
VOLUME
1
TURNOVER
2
52 WEEK HIGH
43.35
52 WEEK LOW
1.100
MARKET CAP
3.35M
P/E (TTM)
-0.0445
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at EIGRQ last week (0506-0510)?
Weekly Report · 5d ago
Weekly Report: what happened at EIGRQ last week (0429-0503)?
Weekly Report · 05/06 10:57
Press Release: Sentynl Therapeutics Announces -2-
The Progeria Research Foundation (PRF) was established in 1999 by the family of Sam Berns. PRF is the only non-profit dedicated to finding treatments and the cure for Progera and its aging-related conditions. Eiger's securityholders are cautioned that trading in its securities is highly speculative and poses substantial risks.
Dow Jones · 05/03 21:00
Press Release: Sentynl Therapeutics Announces Global Acquisition of Zokinvy(R) (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals
Sentynl Therapeutics Announces Global Acquisition of Zokinvy(R) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals in May 2024. Zokinyvy is approved in the U.S. For the treatment of progeria, a collection of ultra-rare, fatal, genetic premature aging diseases.
Dow Jones · 05/03 21:00
Eiger Biopharmaceuticals CFO Exits Amid Bankruptcy Reorganization
TipRanks · 05/02 20:42
Weekly Report: what happened at EIGRQ last week (0422-0426)?
Weekly Report · 04/29 11:02
Weekly Report: what happened at EIGRQ last week (0415-0419)?
Weekly Report · 04/22 10:54
Weekly Report: what happened at EIGRQ last week (0408-0412)?
Weekly Report · 04/15 10:47
More
About EIGRQ
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.

Webull offers Eiger Biopharmaceuticals Inc stock information, including OTCPK: EIGRQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIGRQ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EIGRQ stock methods without spending real money on the virtual paper trading platform.